LENZ Therapeutics Inc (LENZ) - Total Liabilities
Based on the latest financial reports, LENZ Therapeutics Inc (LENZ) has total liabilities worth $21.54 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore LENZ Therapeutics Inc net asset momentum to track the company's year-over-year net asset growth rate.
LENZ Therapeutics Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how LENZ Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
LENZ Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of LENZ Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sensorion SA
PA:ALSEN
|
France | €16.36 Million |
|
Bisalloy Steel Group Ltd
AU:BIS
|
Australia | AU$39.64 Million |
|
Atlan Holdings Bhd
KLSE:7048
|
Malaysia | RM368.32 Million |
|
PBA Holdings Bhd
KLSE:5041
|
Malaysia | RM1.05 Billion |
|
JIUMAOJIU INTL HLDGS LTD
F:3YU
|
Germany | €2.84 Billion |
|
Bien Yapi Urunleri Sanayi Turizm ve Ticaret A.S.
IS:BIENY
|
Turkey | TL13.63 Billion |
|
Lionsgate Studios Holding Corp. (to be renamed Lionsgate Studios Corp.)
NYSE:LION
|
USA | $6.38 Billion |
|
Black Spade Acquisition II Co Unit
NASDAQ:BSIIU
|
USA | $6.81 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down LENZ Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LENZ Therapeutics Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LENZ Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LENZ Therapeutics Inc (2019–2025)
The table below shows the annual total liabilities of LENZ Therapeutics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $21.54 Million | +91.95% |
| 2024-12-31 | $11.22 Million | -93.12% |
| 2023-12-31 | $163.09 Million | +129.31% |
| 2022-12-31 | $71.12 Million | +118.50% |
| 2021-12-31 | $32.55 Million | +0.57% |
| 2020-12-31 | $32.36 Million | +1355.22% |
| 2019-12-31 | $2.22 Million | -- |
About LENZ Therapeutics Inc
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2… Read more